Pirarubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pirarubicin
DrugBank Accession Number
DB11616
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 627.643
Monoisotopic: 627.231575635
Chemical Formula
C32H37NO12
Synonyms
  • Adriamycin, tetrahydropyranyl
  • Pirarubicin
  • Theprubicin
  • THP-Adm
  • THP-Doxorubicin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Pirarubicin.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pirarubicin.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pirarubicin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirarubicin.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pirarubicin hydrochlorideE7V83174BE95343-20-7ZPHYPKKFSHAVOE-YZIXBPQXSA-N

Categories

ATC Codes
L01DB08 — Pirarubicin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes / Monosaccharides
show 11 more
Substituents
1,4-anthraquinone / 9,10-anthraquinone / Acetal / Alcohol / Alkyl aryl ether / Alpha-hydroxy ketone / Amine / Amino saccharide / Aminoglycoside core / Anisole
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
D58G680W0G
CAS number
72496-41-4
InChI Key
KMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yloxy]oxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1

References

General References
Not Available
KEGG Drug
D01885
PubChem Compound
11296583
PubChem Substance
347828009
ChemSpider
9471567
RxNav
33764
ChEBI
94770
ChEMBL
CHEMBL2354444
ZINC
ZINC000014087429
Wikipedia
Pirarubicin

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4Not Yet RecruitingTreatment0.5-14 Year Old Children With Nephroblastoma1somestatusstop reasonjust information to hide
4Unknown StatusTreatmentALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-cell Lymphoma (AITL) / Enteropathy Associated T-cell Lymphoma (EATCL) / Hepato-splenic T-cell Lymphoma / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / Subcutaneous Panniculitis-Like T-Cell Lymphoma1somestatusstop reasonjust information to hide
4Unknown StatusTreatmentBreast Cancer1somestatusstop reasonjust information to hide
4Unknown StatusTreatmentMultiple Myeloma (MM)1somestatusstop reasonjust information to hide
3CompletedTreatmentBreast Neoplasms1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.301 mg/mLALOGPS
logP2.06ALOGPS
logP2.05Chemaxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.99Chemaxon
pKa (Strongest Basic)9.09Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count13Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area204.3 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity157.38 m3·mol-1Chemaxon
Polarizability64.85 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-1113089000-a2d1bb6626733ac774e8
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000t-0009101000-89292464373a9776527d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-3506097000-fc1e03cb6d897eeac34c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00c1-2006092000-303448730314174157ca
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00pi-3680095000-0c433914cf030323e0e3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-005c-2117094000-c6b43ac5bf494e1ea1b1
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-252.2509741
predicted
DarkChem Lite v0.1.0
[M-H]-226.81805
predicted
DeepCCS 1.0 (2019)
[M+H]+252.1489741
predicted
DarkChem Lite v0.1.0
[M+H]+228.9645
predicted
DeepCCS 1.0 (2019)
[M+Na]+251.8530741
predicted
DarkChem Lite v0.1.0
[M+Na]+235.00748
predicted
DeepCCS 1.0 (2019)

Drug created at August 25, 2016 22:58 / Updated at February 21, 2021 18:53